ARTICLE | Clinical News
BI 661051: Phase I started
June 6, 2011 7:00 AM UTC
Boehringer Ingelheim began a double-blind, placebo-controlled, German Phase I trial to compare 2 to 350 mg oral BI 661051 drinking solution vs. placebo in 72 male volunteers. The milestone triggered a...